The one thing on this label your surgeon needs and your telehealth form never asks
These drugs work partly by slowing the stomach down, and a slow stomach is still full when a fasting rule says it should be empty. Both approved labels now carry a warning about pulmonary aspiration during general anesthesia or deep sedation, and both admit in the same breath that the available data are insufficient to say what to do about it. Five medical societies issued joint guidance anyway, because the surgery happens whether the evidence arrives or not.
What this comes down to
- Both labels carry the same warning: rare postmarketing reports of pulmonary aspiration in patients on GLP-1 receptor agonists undergoing procedures requiring general anesthesia or deep sedation, who had residual gastric contents despite reported adherence to preoperative fasting.
- Both labels also state that available data are insufficient to inform recommendations for mitigating that risk. The instruction they do give is to tell your care team about any planned surgery or procedure.
- Zero randomized trials are indexed on this question. The identical filter returns trials of gastric emptying with these drugs, so the filter works.
- Guidance published in 2024 and 2025 by five societies, and a separate multidisciplinary consensus using a modified Delphi process, exists precisely because the trial evidence does not.
What the labels say, and what they decline to say
The tirzepatide label gives the warning its own numbered section and states the mechanism first: the drug delays gastric emptying[1].
“There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations.”
[1]
The sentence that follows is the one that matters most, and it is an admission: available data are insufficient to inform recommendations to mitigate the risk. The semaglutide label carries the same postmarketing report in its adverse reactions section, and its medication guide asks the patient directly whether they are scheduled to have surgery or a procedure using anesthesia or deep sedation[2]. So the label's actual instruction is a communication instruction. Tell people.
A telehealth intake asks about your weight, your history and your medications. A pre-procedure questionnaire asks what you are taking. Neither of them is designed to find out that you started a weekly injection three weeks before a colonoscopy, and the label puts the job of connecting them on you. That is worth knowing before a routine procedure, not after one.
PubMed, via the E-utilities API
(semaglutide[tiab] OR tirzepatide[tiab] OR "GLP-1 receptor agonist"[tiab]) AND ("pulmonary aspiration"[tiab] OR "residual gastric content"[tiab]) AND "randomized controlled trial"[pt] AND "humans"[mh]Returned 0. Positive control — semaglutide and gastric emptying, identical trial filter — returned 6 through the identical filter in the same session.
The control is deliberately the adjacent question rather than an unrelated drug, because what needs testing is whether the filter can find randomized work on gastric physiology with these drugs. It can — six trials. Dropping the trial filter, the aspiration and residual-content query returns 40 records: reviews, case reports, cohorts and guidance documents. What nobody has run is a randomized comparison of one preoperative strategy against another.
What the societies did with nothing
In 2024 and 2025 a joint clinical practice guidance on the safe use of these drugs in the perioperative period was published across several journals, issued by the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the American Society of Anesthesiologists, the International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons[3]. A separate 2025 consensus statement led by the Society for Perioperative Assessment and Quality Improvement used a modified Delphi process supported by a systematic review, and addressed both perioperative management of these drugs and preoperative fasting times for solids and liquids[4].
A review in the endocrinology literature lays out why a clean answer is hard: these drugs have long half-lives; the receptor slows gastric emptying even at physiological concentrations; the effect diminishes with prolonged treatment; and in people whose gastric emptying was already slow, the additional effect is limited. It suggests longer fasting for solids, point-of-care ultrasound for retained gastric content, and prokinetic drugs as approaches needing further study[5]. Those are research directions rather than a rule, and we are not the people to turn them into one. Forty records discuss aspiration or residual gastric content with these drugs, and none of them is a randomized trial[6].
What this changes about buying one online
- Write down the drug, the dose and the date you started, and carry that to any procedure. The label asks for exactly this and provides no other mitigation.
- A compounded vial makes the disclosure harder, not easier, because the strength and the name on the label may not match anything a pre-procedure form recognizes. Milligrams, milliliters and units is the article about that mismatch.
- Delayed gastric emptying is also the mechanism behind the interaction with oral medications, including the one place only one of these labels warns about birth control.
- If a seller's intake never asks about upcoming procedures, that is a data point about the seller. How a telehealth prescription actually happens covers what those forms do and do not collect.
Questions people actually ask
Do I need to stop a GLP-1 before surgery?
Nobody on this site holds a medical license, and the labels themselves say the available data are insufficient to inform recommendations for mitigating the risk. What both labels do instruct is to inform your health care providers of any planned surgeries or procedures.
What exactly is the risk?
Pulmonary aspiration under general anesthesia or deep sedation. Both labels record rare postmarketing reports in patients who had residual gastric contents despite reported adherence to preoperative fasting recommendations, which is what a drug that slows the stomach would be expected to cause.
Has anyone tested what to do about it?
Not in a randomized trial. PubMed indexes none on this question, while the identical filter returns six randomized trials of gastric emptying with semaglutide, so the search is capable of finding work in this area. The guidance that exists is consensus built on top of observational data.
Does this apply to compounded versions too?
The mechanism belongs to the molecule, so there is no reason to expect a compounded preparation of the same drug to behave differently. What is harder with a compounded product is telling a pre-procedure team precisely what you took and at what strength.
Sources
Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it. All of it was read in September 2026, the same session the rest of this page draws on.
- 1.ZEPBOUND (tirzepatide) injection — FDA prescribing information. DailyMed, National Library of Medicine, Structured Product Labeling, 2026. Source · Document dated August 2026Section 5.9 of the SPL with effective time 20260828, Pulmonary Aspiration During General Anesthesia or Deep Sedation, states that the drug delays gastric emptying, carries the quoted postmarketing report about residual gastric contents despite reported adherence to preoperative fasting, and states that available data are insufficient to inform recommendations to mitigate the risk. Its highlights direct patients to inform health care providers of any planned surgeries or procedures.
- 2.WEGOVY (semaglutide) injection and tablets — FDA prescribing information. DailyMed, National Library of Medicine, Structured Product Labeling, 2026. Source · Document dated June 2026The SPL with effective time 20260618 records, among postmarketing reports, pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation. Its medication guide asks the patient to tell the prescriber if they are scheduled to have surgery or other procedures that use anesthesia or deep sedation. Its drug interactions section states the drug delays gastric emptying and may impact absorption of concomitantly administered oral medications.
- 3.Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period. Clinical Gastroenterology and Hepatology, 2025. PMID 39480373 · doi:10.1016/j.cgh.2024.10.003The PubMed record lists the issuing bodies as the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the American Society of Anesthesiologists, the International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons, and the guidance was also published in Surgery for Obesity and Related Diseases in 2024 and in Surgical Endoscopy in 2025.
- 4.Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement consensus statement. British Journal of Anaesthesia, 2025. PMID 40379536 · doi:10.1016/j.bja.2025.04.001A multidisciplinary consensus statement led by the Society for Perioperative Assessment and Quality Improvement, providing updated recommendations based on a modified Delphi process and supported by a systematic review, addressing perioperative management of GLP-1 receptor agonists and preoperative fasting times for solids and liquids, with the systematic review registered on PROSPERO as CRD42023438624.
- 5.Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. Journal of Clinical Endocrinology and Metabolism, 2024. PMID 39418085 · doi:10.1210/clinem/dgae719The review states that recommendations for periprocedural management of these drugs are compromised by limited evidence, and names as relevant factors their long half-lives, the capacity of GLP-1 receptor agonism to slow gastric emptying even at physiological concentrations, tachyphylaxis with prolonged treatment, and the limited additional effect in people whose gastric emptying was already slow. It concludes that prolonged fasting for solids, point-of-care ultrasound for retained gastric content and prokinetic medication may prove helpful and represent an area needing further study.
- 6.PubMed, queried through the E-utilities API. National Library of Medicine, 2026. SourceOn 2026-09-12, these drugs with a pulmonary aspiration or residual gastric content term through the randomized-trial and human-indexing filter returned 0; the same terms without the trial filter returned 40; semaglutide with a gastric emptying term through the identical trial filter returned 6 and semaglutide alone returned 316.
Key figures